CONCORD, Mass., Oct. 28, 2019 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation,

DENVER, Oct. 28, 2019 /PRNewswire/ -- Rx Green Technologies, www.rxgreentechnologies.com, a leader in cannabis nutrients, substrates, and pest management has partnered with

REDWOOD CITY, Calif., Oct. 28, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Wednesday, November 6, 2019. AcelRx management will host a live webcast and conference call at

WASHINGTON, Oct. 28, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Anne Sempowski Ward has joined the company's Board of Directors, effective October 28, 2019. Following Ms. Ward's appointment, Vanda's Board of Directors is now comprised of six directors.

TOLEDO, Ohio, Oct. 28, 2019 /PRNewswire/ -- Welltower Inc. (NYSE: WELL) today announced results for the quarter ended September 30, 2019.

ROCKVILLE, Md., Oct. 28, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to deve

BIRMINGHAM, Ala., Oct. 28, 2019 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC), a national leader in integrated healthcare, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies, today reported its results of operations for the third quarter ended September 30, 201

WASHINGTON, Oct. 28, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will be presenting at the Baird Global Industrial Conference in Chicago on Tuesday, November 5, 2019 at

SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the first clinical results from its Phase 1/2 trial evaluating MRTX849, an investigational KRAS G12C inhibitor, in patients with solid tumors expressing KRAS G12C mutations. MRTX849 demonstrated clinical activity, including object

NEWPORT BEACH, Calif. and WATERTOWN, Mass., Oct. 28, 2019 /PRNewswire/ -- UFC GYM®, the rapidly expanding fitness franchise that creates training programs fo